Clindamycin: Potent Antibiotic for Serious Bacterial Infections
Clindamycin
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.43 | $43.00 (0%) | π Add to cart |
| 60 | $1.22 | $86.00 $73.00 (15%) | π Add to cart |
| 90 | $1.17 | $129.00 $105.00 (19%) | π Add to cart |
| 120 | $1.13 | $172.00 $136.00 (21%) | π Add to cart |
| 180 | $1.09 | $258.00 $196.00 (24%) | π Add to cart |
| 270 | $1.07
Best per pill | $387.00 $289.00 (25%) | π Add to cart |
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.60 | $48.00 (0%) | π Add to cart |
| 60 | $1.38 | $96.00 $83.00 (14%) | π Add to cart |
| 90 | $1.31 | $144.00 $118.00 (18%) | π Add to cart |
| 120 | $1.27 | $192.00 $152.00 (21%) | π Add to cart |
| 180 | $1.24 | $288.00 $223.00 (23%) | π Add to cart |
| 270 | $1.21
Best per pill | $432.00 $326.00 (25%) | π Add to cart |
Synonyms | |||
Clindamycin is a lincosamide-class antibiotic prescribed for the treatment of a wide spectrum of serious anaerobic and aerobic gram-positive bacterial infections. Its mechanism of action involves binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and leading to bacteriostatic or bactericidal effects depending on the organism and drug concentration. This makes it a critical agent in managing skin and soft tissue infections, intra-abdominal infections, and bone/joint infections, particularly where penicillin is not an option. Its ability to penetrate bone, abscesses, and phagocytic cells enhances its efficacy in deep-seated and polymicrobial infections.
Features
- Pharmacological Class: Lincosamide antibiotic
- Available Forms: Oral capsules (150 mg, 300 mg), topical solutions/gels (1%), vaginal creams/ovules (2%), and injectable solutions for intravenous or intramuscular administration
- Mechanism of Action: Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis
- Spectrum of Activity: Effective against many aerobic gram-positive cocci (e.g., Staphylococcus aureus, Streptococcus pneumoniae) and anaerobic bacteria (e.g., Bacteroides fragilis, Clostridium perfringens)
- Bioavailability: Approximately 90% for oral administration, with peak serum concentrations reached within 45 minutes
- Half-life: Ranges from 2 to 3 hours in adults with normal renal function
Benefits
- Provides potent activity against methicillin-sensitive Staphylococcus aureus (MSSA) and streptococci, making it a valuable option for skin and soft tissue infections.
- Demonstrates excellent efficacy against anaerobic bacteria, which is crucial for treating polymicrobial infections like intra-abdominal abscesses and pelvic inflammatory disease.
- Offers good tissue penetration, achieving therapeutic concentrations in bone, joints, and abscess fluid, sites that are often difficult for other antibiotics to reach effectively.
- Serves as a reliable alternative for patients with serious beta-lactam (penicillin) allergies who require coverage for gram-positive and anaerobic organisms.
- Available in multiple formulations (oral, topical, parenteral) allowing for tailored treatment regimens from severe systemic infection to localized topical application.
Common use
Clindamycin is indicated for the treatment of infections caused by susceptible strains of designated microorganisms. Its primary uses include serious infections caused by anaerobic bacteria, such as those originating in the respiratory tract, abdomen, and female genital tract (e.g., pelvic inflammatory disease, endometritis). It is also commonly prescribed for skin and soft tissue infections, including abscesses, cellulitis, and wound infections caused by Staphylococcus aureus and Streptococcus pyogenes. Furthermore, it is used for septicemia and as adjunctive therapy in chronic bone and joint infections, particularly osteomyelitis caused by susceptible organisms. Topical formulations are used for the treatment of acne vulgaris.
Dosage and direction
Dosage is highly dependent on the severity of the infection, the causative organism, and the patient’s hepatic and renal function.
- Adults, Serious Infections (Oral): 150 to 450 mg every 6 hours.
- Adults, More Severe Infections (Oral): 300 to 450 mg every 6 hours.
- Adults (Parenteral - IV/IM): For serious infections, 600 to 1200 mg per day, divided into 2, 3, or 4 equal doses (e.g., 600 mg IV every 8 hours). For more severe infections, 1200 to 2700 mg per day, divided.
- Children (Parenteral - IV/IM): 20 to 40 mg/kg/day based on the severity of the infection, divided into 3 or 4 equal doses.
- Topical (Acne): Apply a thin layer to the affected area twice daily.
- Vaginal (Bacterial Vaginosis): Apply one full applicator (5 grams) of cream intravaginally at bedtime for 7 consecutive days, or insert one ovule intravaginally at bedtime for 3 days.
Direction: Oral capsules should be taken with a full glass of water to minimize the risk of esophageal irritation. Patients should complete the entire prescribed course of therapy, even if symptoms improve, to prevent the development of drug-resistant bacteria.
Precautions
- Clostridium difficile-Associated Diarrhea (CDAD): Antibiotic use, including clindamycin, can cause a potentially life-threatening overgrowth of C. difficile, resulting in severe diarrhea and colitis. This can occur during or several months after therapy. If significant diarrhea occurs, the drug should be discontinued and the patient evaluated.
- Hepatic and Renal Impairment: Use with caution in patients with significant liver disease or severe renal impairment. Serum drug level monitoring may be advisable in severe cases, and dosage adjustments might be necessary.
- Superinfection: Use may result in overgrowth of non-susceptible organisms, particularly fungi. The patient should be monitored for any new infections.
- Pregnancy and Lactation: Clindamycin crosses the placental barrier and is excreted in breast milk. It should be used during pregnancy and lactation only if clearly needed, weighing the potential benefits against the risks to the fetus or infant.
Contraindications
Clindamycin is contraindicated in patients with a known hypersensitivity to clindamycin, lincomycin, or any component of the formulation. It is also contraindicated in patients who have previously experienced CDAD with its use.
Possible side effect
Common side effects include nausea, vomiting, abdominal pain, diarrhea, and unpleasant or metallic taste. Skin rashes and transient elevations in liver enzymes may also occur. More serious side effects require immediate medical attention and include:
- Watery or bloody diarrhea (may be a sign of CDAD)
- Severe skin reactions (e.g., rash, blistering, peeling)
- Jaundice (yellowing of the skin or eyes)
- Signs of an allergic reaction (hives, difficulty breathing, swelling of the face or throat)
- Unusual fatigue, dark urine, clay-colored stools (signs of liver dysfunction)
Drug interaction
- Neuromuscular Blocking Agents: Clindamycin may enhance the action of neuromuscular blocking agents (e.g., pancuronium), potentially prolonging respiratory depression.
- Erythromycin and Chloramphenicol: These drugs are antagonistic to clindamycin and should not be administered concurrently.
- Kaolin-Pectin: This anti-diarrheal agent can decrease the absorption of oral clindamycin.
- CYP3A4/5 Inducers/Inhibitors: As a minor substrate of these enzymes, interactions with strong inducers (e.g., rifampin) or inhibitors may be possible, though clinical significance is often low.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not double the dose to make up for a missed one.
Overdose
Symptoms of overdose would be an extension of the drug’s known adverse effects, primarily severe gastrointestinal distress (nausea, vomiting, diarrhea). CDAD is a significant risk. Management is supportive; there is no specific antidote. Gastric lavage may be considered if ingestion was recent. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the blood.
Storage
Store at room temperature (20Β°C to 25Β°C or 68Β°F to 77Β°F), away from light, moisture, and heat. Do not freeze. Oral solutions prepared from the powder should be stored in the refrigerator and discarded after 2 weeks. Keep all medications out of the reach of children and pets.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
- “As an infectious disease specialist, clindamycin remains a cornerstone of my arsenal for anaerobic coverage, especially in penicillin-allergic patients. Its bone penetration is particularly valuable in orthopedic infections.” β Dr. A., MD, Infectious Disease
- “While highly effective, the specter of C. diff is always present. I reserve its use for confirmed anaerobic infections where the benefit clearly outweighs the risk and ensure my patients are thoroughly counseled on the signs of CDAD.” β Dr. L., MD, Internal Medicine
- “The topical formulation has been a game-changer for many of my patients with moderate to severe inflammatory acne, offering a potent anti-inflammatory and antibacterial effect with minimal systemic exposure.” β Dr. P., Dermatologist
- “From a clinical pharmacy perspective, its multiple formulations allow for seamless transitions from IV to PO therapy, facilitating early discharge and outpatient parenteral antibiotic therapy (OPAT). Monitoring for diarrhea is our top priority.” β Clinical Pharmacist, BCOP